# Beta Alethine in Treating Patients With Low-Grade Lymphoma

> **NCT00007839** · PHASE1,PHASE2 · UNKNOWN · sponsor: **LifeTime Pharmaceuticals**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** beta alethine

## Key facts

- **NCT ID:** NCT00007839
- **Lead sponsor:** LifeTime Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00007839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00007839, "Beta Alethine in Treating Patients With Low-Grade Lymphoma". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00007839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*